U.S. Markets open in 5 hrs 6 mins

Radius Health, Inc. (RDUS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.91-0.39 (-3.45%)
At close: 4:00PM EDT
Sign in to post a message.
  • g
    g
    Good morning all,
    I don’t know about the rest of you, but I am encouraged how the stock price is holding during this time. Obviously I would like for it to be much higher but considering the current environment this is encouraging to me.

    Thoughts?
  • P
    Phillip
    patch enrollment complete. Thats good news even if nobody wants to reward the stock.
  • P
    Phillip
    Beat on revenue. Patch trial still on schedule. 12 months of cash on balance sheet. pretty good news for the most part - nothing thats going to double the stock price in the short term.
  • T
    Tom
    I like this part...

    "Radius will continue to be responsible for the conduct and completion of the Phase 3 EMERALD study through NDA filing. Costs associated with this activity will be reimbursed by Menarini Group"
  • M
    Milad
    News out on Elacestrant
  • K
    Kevin
    the partnerships have been no help to the stock price
  • K
    Kevin
    whelp, even though this partnership is good news... I wish I sold this a long time age to put more money in gold and silver. good thing I did that with most of my money.
  • g
    g
    Earnings date quickly approaching . Must have strong guidance, positive results and continued focus on aggressive results from trials. All while reducing spend. You have developed the product, expanded pipeline and sales force, time to tighten belt and show results.
  • S
    Stocktargetadvisor
    $RDUS
    Target Lowered by Citigroup Buy USD 39 » USD 25
    Target Lowered by Jefferies Neutral » Hold USD 17 » USD 14
  • C
    Chi
    BIOTECH TARGET N V, 10%-Owner of Radius Health, Inc. BOUGHT 25000 shares on 2020-07-08. https://formwhispers.com/s?t=RDUS
    FormWhispers - Trading Ideas from Insiders Radius Health, Inc. RDUS.
    FormWhispers - Trading Ideas from Insiders Radius Health, Inc. RDUS.
    formwhispers.com
  • g
    g
    So what’s the reason for the drop today?
  • S
    Steve
    Great buying opportunity today, completely oversold. No negative news. Solid Q3 earnings. The news about Elacestrant future partnership wasn’t taken well, but doesn’t justify a share price move from 30 to 21. Nor does Evenity approval in EU.
    We should see continued revenue growth in Q4, along with solid 2020 revenue guidance. We should see 2020 full year sales somewhere around 250-300 million or more. Current market cap of RDUS is $972 million...
  • T
    Tom
    Raduis presentation at JP Morgan Conference at 2pm EST today the 8th / Looking forward to an update from Mr Hoiland
  • A
    ARIF
    Some relief to see today’s price action after what seems like an eternity. I would like to see volume pick up and it holds $30 plus by closing and, hopefully this momentum continues in coming days.
  • A
    ARIF
    I have secured the financing and will take this company private at $50.
  • M
    Marco
    what has changed since 2018
    1. stock is in a long term uptrend and has an open gap at 25-27
    2. stock is oversold and has built positive divergencies on a 5 year chart
    3. Trey has not learned anything in live and still believes to be the oracle of Delphi and having the right to abuse people
    4. Strategie: start to go long on weak days, use option strategy to go in, sell 17.5 July put for 2.5, buy 20 July call at 3.5 for a net debit of 1
    5. we might continue so see a bit of a bumpy ride for the time being but risk reward seems to be positive around this level for the next 6-12 months
    6. don't be greedy, start small and once the trend goes into your direction add to your position, first target 25-27
  • G
    GC
    Prescriptions rising nicely!

    Tymlos growth reflects access expansion
    As we enter the new year, Tymlos is gaining formulary exclusivity from Express Scripts’
    commercial business, which represents approximately 11% of total lives. Accordingly, we
    closely monitor Tymlos and Forteo scripts and note that Tymlos New to Brand (NBRx)
    scripts and total scripts (TRx) increased 43% and 25%, significantly outpacing
    competitor Forteo’s NBRx growth of 3% and TRx decrease of 18% while the overall
    anabolics market NBRx increased 12% and TRx decreased 15% in the week ending
    01/05/18. Of note, NBRx is the number of new patients coming onto a therapy class. In
    our view, Tymlos’ NBRx trend could be a leading indicator for TRx and an effective
    measure on patient acquisition. As of January 3, 2018, Tymlos had access to
    approximately 214M covered lives compared to 268M lives for Forteo in the US.
    However, since its launch, Tymlos has steadily gained NBRx market share to 29% in the
    week ending 01/05/08 (Chart 1). We see 50% Tymlos share of NBRx by end of 2018.
    For the week ending January 12, IMS reported 271 NRx and 496 TRx of Tymlos,
    representing 15% and 8% market share, respectively. We believe Tymlos’ upward script
    trends in January provide positive signals for its continued patient acquisitions through
    switches as well as expansion of the overall anabolics market (Chart 2). We maintain our
    Buy rating on RDUS.

    Excerpt from ML report.
  • A
    ARIF
    So what to make of the results and any predictions for tomorrow? Any insights on conference call would be welcome.
  • M
    Marco
    Thank you for the upgrade sold half my position at 36.5 as i still believe we are range bound for the time being, happy Eastern and Passover